RS204A - Phenylsulfonyl-1,3-dihydro-2h-indole-2- one derivatives,their preparation and their therapeutic use - Google Patents

Phenylsulfonyl-1,3-dihydro-2h-indole-2- one derivatives,their preparation and their therapeutic use

Info

Publication number: RS204A
Authority: RS; Serbia
Prior art keywords: preparation; phenylsulfonyl; indole; dihydro; derivatives
Prior art date: 2001-07-17

Application number

YU204A

Other languages

English (en)

Serbian (sr)

Inventor

Alain Di Malta

Georges Garcia

Richard Roux

Bruno Schoentjes

Gal Claudine Serradeil-Le

Bernard Tonnerre

Jean Wagnon

Original Assignee

Sanofi-Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-17

Filing date

2002-07-15

Publication date

2006-12-15

2002-07-15 Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis

2006-12-15 Publication of RS204A publication Critical patent/RS204A/sr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Addiction (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)

YU204A 2001-07-17 2002-07-15 Phenylsulfonyl-1,3-dihydro-2h-indole-2- one derivatives,their preparation and their therapeutic use RS204A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0110359A FR2827604B1 (fr)	2001-07-17	2001-07-17	Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
PCT/FR2002/002500 WO2003008407A2 (fr)	2001-07-17	2002-07-15	Derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
RS204A true RS204A (en)	2006-12-15

Family

ID=8866211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
YU204A RS204A (en)	2001-07-17	2002-07-15	Phenylsulfonyl-1,3-dihydro-2h-indole-2- one derivatives,their preparation and their therapeutic use

Country Status (32)

Country	Link
US (1)	US7119086B2 (fr)
EP (1)	EP1419150B1 (fr)
JP (1)	JP4262088B2 (fr)
KR (1)	KR20040017325A (fr)
CN (1)	CN1224623C (fr)
AR (1)	AR034792A1 (fr)
AT (1)	ATE294171T1 (fr)
AU (1)	AU2002340999B2 (fr)
BR (1)	BR0211284A (fr)
CA (1)	CA2450437A1 (fr)
CO (1)	CO5550440A2 (fr)
DE (1)	DE60203917T2 (fr)
DK (1)	DK1419150T3 (fr)
EA (1)	EA006019B1 (fr)
ES (1)	ES2240814T3 (fr)
FR (1)	FR2827604B1 (fr)
HK (1)	HK1061679A1 (fr)
HR (1)	HRP20040027A2 (fr)
HU (1)	HUP0401461A3 (fr)
IL (1)	IL159275A0 (fr)
IS (1)	IS2485B (fr)
MA (1)	MA27049A1 (fr)
ME (1)	MEP24508A (fr)
MX (1)	MXPA04000507A (fr)
NO (1)	NO20040219L (fr)
NZ (1)	NZ530144A (fr)
PL (1)	PL366829A1 (fr)
PT (1)	PT1419150E (fr)
RS (1)	RS204A (fr)
UA (1)	UA77181C2 (fr)
WO (1)	WO2003008407A2 (fr)
ZA (1)	ZA200309717B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7754711B2 (en) *	2003-07-30	2010-07-13	Xenon Pharmaceuticals Inc.	Pyridazine derivatives and their use as therapeutic agents
WO2005018531A2 (fr) *	2003-08-26	2005-03-03	'chemical Diversity Research Institute', Ltd.	Compositions pharmaceutiques, composes azo-heterocycliques et procedes de fabrication et d'utilisation correspondants
EP1659121A4 (fr)	2003-08-28	2008-11-26	Taisho Pharmaceutical Co Ltd	D riv de 1,3-dihydro-2h-indol-2-one
US8580842B2 (en) *	2003-09-30	2013-11-12	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) *	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
BRPI0510260A (pt)	2004-04-27	2007-10-23	Wyeth Corp	método para purificar um composto, e, kit farmacêutico
DE102004033834A1 (de) *	2004-07-13	2006-02-02	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
EP1842555A4 (fr) *	2004-12-27	2009-08-19	Univ Kyoto	Inhibiteur de developpement de tolerance destine a un agent analgesique narcotique
US8030499B2 (en)	2005-01-28	2011-10-04	Taisho Pharmaceutical Co., Ltd.	1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
WO2006100082A2 (fr)	2005-03-24	2006-09-28	Abbott Gmbh & Co. Kg	Derives d'oxindole substitues, medicaments contenant ces derives et leur utilisation
DE102005014936A1 (de) *	2005-03-24	2006-12-14	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014904A1 (de)	2005-03-26	2007-02-01	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
US7576082B2 (en)	2005-06-24	2009-08-18	Hoffman-La Roche Inc.	Oxindole derivatives
SG132540A1 (en)	2005-11-25	2007-06-28	Matsushita Electric Ind Co Ltd	Magnetic trap for ferrous contaminants in lubricant
US8044079B2 (en)	2005-12-02	2011-10-25	Abbott Gmbh & Co. Kg	Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
DE102006040915A1 (de) *	2006-08-26	2008-03-20	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
EP2061769A1 (fr) *	2006-08-26	2009-05-27	Abbott GmbH & Co. KG	Dérivés de benzimidazolone substitués, médicaments les comprenant, et leurs utilisations
US20080167286A1 (en)	2006-12-12	2008-07-10	Abbott Laboratories	Pharmaceutical compositions and their methods of use
US8486979B2 (en) *	2006-12-12	2013-07-16	Abbvie Inc.	1,2,4 oxadiazole compounds and methods of use thereof
RU2461556C2 (ru) *	2006-12-30	2012-09-20	Эбботт Гмбх Унд Ко. Кг	Замещенные производные оксидола и их применение в качестве лигандов рецептора вазопрессина
UY30846A1 (es)	2006-12-30	2008-07-31	Abbott Gmbh & Amp	Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CN101611028B (zh) *	2006-12-30	2013-09-11	艾博特股份有限两合公司	取代的羟吲哚衍生物、以及它们用作加压素受体配体的用途
US8486931B2 (en) *	2007-03-02	2013-07-16	Abbott Gmbh & Co. Kg	Substituted oxindole compounds
FR2920023B1 (fr) *	2007-08-16	2013-02-08	Sanofi Aventis	Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
JP5645217B2 (ja) *	2007-12-07	2014-12-24	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
US8703774B2 (en)	2007-12-07	2014-04-22	AbbVie Deutschland GmbH & Co. KG	Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
WO2009071691A2 (fr) *	2007-12-07	2009-06-11	Abbott Gmbh & Co. Kg	Dérivés oxindoliques et leur utilisation comme médicament
JP5595926B2 (ja) *	2007-12-07	2014-09-24	アボットゲーエムベーハーウントカンパニーカーゲー	５−ハロゲン−置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
ES2398676T3 (es)	2007-12-07	2013-03-20	Abbott Gmbh & Co. Kg	Derivados de oxindol sustituidos con amidometilo y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina
EP2227463B1 (fr) *	2007-12-27	2016-08-17	AbbVie Deutschland GmbH & Co KG	Dérivés substitués d'oxindole et leur utilisation pour le traitement de maladies dépendant de la vasopressine
FR2927625B1 (fr) *	2008-02-19	2010-03-12	Sanofi Aventis	Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) *	2008-04-21	2010-05-14	Sanofi Aventis	Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
WO2010017827A1 (fr) *	2008-08-14	2010-02-18	European Molecular Biology Laboratory	Dérivés 1-sulfonyl-2,3-dihydro-indoles substitués en position 6 destinés au traitement de maladies prolifératives
MX349717B (es)	2008-10-17	2017-08-09	Sanofi Aventis Deutschland	Combinación de una insulina y un agonista de glp-1.
FR2941947B1 (fr)	2009-02-12	2011-03-25	Sanofi Aventis	Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
FR2941946B1 (fr)	2009-02-12	2011-03-25	Sanofi Aventis	Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
US9040568B2 (en)	2009-05-29	2015-05-26	Abbvie Inc.	Pharmaceutical compositions for the treatment of pain
CA2763931A1 (fr) *	2009-06-10	2010-12-16	Abbott Gmbh & Co. Kg	Utilisation de derives substitues de l'oxindole pour le traitement et la prophylaxie de la douleur
HUE037735T2 (hu)	2009-11-13	2018-09-28	Sanofi Aventis Deutschland	DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
TR201809460T4 (tr)	2009-11-13	2018-07-23	Sanofi Aventis Deutschland	Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
US8088815B2 (en)	2009-12-02	2012-01-03	Hoffman-La Roche Inc.	Spiroindolinone pyrrolidines
US8288431B2 (en)	2010-02-17	2012-10-16	Hoffmann-La Roche Inc.	Substituted spiroindolinones
US8217044B2 (en)	2010-04-28	2012-07-10	Hoffmann-La Roche Inc.	Spiroindolinone pyrrolidines
AU2011202239C1 (en) *	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
SI2611458T1 (sl)	2010-08-30	2017-01-31	Sanofi-Aventis Deutschland Gmbh	Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
CN103380127B (zh)	2010-12-21	2016-08-10	拜耳知识产权有限责任公司	制备n-磺酰基取代的羟吲哚的方法
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru)	2011-08-29	2018-04-16	Санофи-Авентис Дойчланд Гмбх	Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2983697B1 (fr)	2013-04-03	2018-10-31	Sanofi	Traitement du diabète sucré par de nouveaux dosages d'insuline glargine
SI3229828T1 (sl)	2014-12-12	2023-06-30	Sanofi-Aventis Deutschland Gmbh	Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
EP3912625A1 (fr) *	2020-05-20	2021-11-24	Kaerus Bioscience Limited	Nouveaux ouvreurs de canaux potassiques maxi-k pour le traitement de troubles liés à l'x fragile
KR20230090589A (ko) *	2021-12-15	2023-06-22	국립해양생물자원관	성게 유래 펩타이드 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2714378B1 (fr)	1993-12-24	1996-03-15	Sanofi Sa	Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
GB2326639A (en) *	1997-06-18	1998-12-30	Merck & Co Inc	Piperazine Oxytocin Receptor Antagonists
US20050070718A1 (en) *	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them

2001
- 2001-07-17 FR FR0110359A patent/FR2827604B1/fr not_active Expired - Fee Related
2002
- 2002-07-15 DE DE60203917T patent/DE60203917T2/de not_active Expired - Lifetime
- 2002-07-15 AU AU2002340999A patent/AU2002340999B2/en not_active Ceased
- 2002-07-15 DK DK02774822T patent/DK1419150T3/da active
- 2002-07-15 US US10/484,370 patent/US7119086B2/en not_active Expired - Fee Related
- 2002-07-15 AT AT02774822T patent/ATE294171T1/de active
- 2002-07-15 PL PL02366829A patent/PL366829A1/xx not_active Application Discontinuation
- 2002-07-15 PT PT02774822T patent/PT1419150E/pt unknown
- 2002-07-15 EP EP02774822A patent/EP1419150B1/fr not_active Expired - Lifetime
- 2002-07-15 CN CNB028142624A patent/CN1224623C/zh not_active Expired - Fee Related
- 2002-07-15 CA CA002450437A patent/CA2450437A1/fr not_active Abandoned
- 2002-07-15 KR KR10-2004-7000787A patent/KR20040017325A/ko active IP Right Grant
- 2002-07-15 UA UA20031212069A patent/UA77181C2/uk unknown
- 2002-07-15 ES ES02774822T patent/ES2240814T3/es not_active Expired - Lifetime
- 2002-07-15 ME MEP-245/08A patent/MEP24508A/xx unknown
- 2002-07-15 JP JP2003513966A patent/JP4262088B2/ja not_active Expired - Fee Related
- 2002-07-15 HU HU0401461A patent/HUP0401461A3/hu unknown
- 2002-07-15 IL IL15927502A patent/IL159275A0/xx unknown
- 2002-07-15 RS YU204A patent/RS204A/sr unknown
- 2002-07-15 NZ NZ530144A patent/NZ530144A/en not_active IP Right Cessation
- 2002-07-15 BR BR0211284-1A patent/BR0211284A/pt not_active IP Right Cessation
- 2002-07-15 WO PCT/FR2002/002500 patent/WO2003008407A2/fr active IP Right Grant
- 2002-07-15 MX MXPA04000507A patent/MXPA04000507A/es active IP Right Grant
- 2002-07-15 EA EA200301306A patent/EA006019B1/ru not_active IP Right Cessation
- 2002-07-16 AR ARP020102655A patent/AR034792A1/es unknown
2003
- 2003-12-15 ZA ZA200309717A patent/ZA200309717B/en unknown
- 2003-12-15 IS IS7079A patent/IS2485B/is unknown
2004
- 2004-01-09 MA MA27476A patent/MA27049A1/fr unknown
- 2004-01-12 HR HR20040027A patent/HRP20040027A2/xx not_active Application Discontinuation
- 2004-01-14 CO CO04002002A patent/CO5550440A2/es not_active Application Discontinuation
- 2004-01-16 NO NO20040219A patent/NO20040219L/no not_active Application Discontinuation
- 2004-06-25 HK HK04104546A patent/HK1061679A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP0401461A3 (en)	2009-06-29
DE60203917T2 (de)	2006-02-16
NO20040219L (no)	2004-03-17
IS7079A (is)	2003-12-15
JP4262088B2 (ja)	2009-05-13
CN1533387A (zh)	2004-09-29
FR2827604A1 (fr)	2003-01-24
UA77181C2 (en)	2006-11-15
ES2240814T3 (es)	2005-10-16
ATE294171T1 (de)	2005-05-15
CA2450437A1 (fr)	2003-01-30
ZA200309717B (en)	2004-12-15
KR20040017325A (ko)	2004-02-26
BR0211284A (pt)	2004-08-03
DE60203917D1 (de)	2005-06-02
CN1224623C (zh)	2005-10-26
EA200301306A1 (ru)	2004-06-24
US7119086B2 (en)	2006-10-10
EA006019B1 (ru)	2005-08-25
JP2004536131A (ja)	2004-12-02
HRP20040027A2 (en)	2004-06-30
MEP24508A (en)	2010-10-10
EP1419150A2 (fr)	2004-05-19
FR2827604B1 (fr)	2003-09-19
WO2003008407A3 (fr)	2003-10-16
AU2002340999B2 (en)	2007-03-01
HK1061679A1 (en)	2004-09-30
MXPA04000507A (es)	2004-07-23
EP1419150B1 (fr)	2005-04-27
DK1419150T3 (da)	2005-08-29
MA27049A1 (fr)	2004-12-20
IL159275A0 (en)	2004-06-01
HUP0401461A2 (hu)	2004-12-28
AR034792A1 (es)	2004-03-17
US20040180878A1 (en)	2004-09-16
WO2003008407A2 (fr)	2003-01-30
PT1419150E (pt)	2005-08-31
NZ530144A (en)	2005-03-24
CO5550440A2 (es)	2005-08-31
PL366829A1 (en)	2005-02-07
IS2485B (is)	2008-12-15

Publication	Publication Date	Title
MXPA04000507A (es)	2004-07-23	Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, su preparacion y uso terapeutico.
YU52302A (sh)	2006-05-25	Novi derivati 1,3-dihidro-2h-indol-2-ona i njihova upotreba kao liganada za v1b i v1a receptore arginin-vazopresina
ATE316083T1 (de)	2006-02-15	Adamantanderivate
AU2003228770A1 (en)	2003-11-11	Substituted pyrazolopyrimidines
DE69924480D1 (en)	2005-05-04	Pyrazolderivative als p-38 map kinase inhibitoren
AU2001235596A1 (en)	2001-08-07	Novel 1,3-dihydro-2h-indol-2-one derivatives, preparation method and pharmaceutical compositions containing them
IL161074A0 (en)	2004-08-31	Lactam derivatives as antagonists for human 11cby receptors
AU2002239344A1 (en)	2002-06-24	Pyrazolopyridines
MY136430A (en)	2008-10-31	N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
YU80902A (sh)	2005-11-28	Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
BR0014225A (pt)	2002-05-21	Derivados de pirazol
HK1070054A1 (en)	2005-06-10	Arylsulfonyl derivatives with5-ht6 receptor affinity
WO2002048148A3 (fr)	2003-05-01	Composes therapeutiques
WO2001064668A3 (fr)	2002-03-14	Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de l'argine-vasopressine
GB0109122D0 (en)	2001-05-30	Novel compounds
MXPA04005426A (es)	2004-10-11	Derivados de pirazol de anillos fuisionados.
AU2002248531A1 (en)	2002-09-24	Pyrazolopyriadine derivatives
YU86603A (sh)	2006-05-25	Novi derivati piperidinkarboksamida, postupak za njihovo pripremanje i farmaceutske kompozicije koje ih sadrže
AU2002357740A1 (en)	2003-06-23	Pyrazolo-pyridine derivatives as antiherpes agents
CA2443012A1 (fr)	2002-11-07	Utilisation de derives de pyridoindolone pour la preparation de medicaments
MXPA04000952A (es)	2004-04-20	Sales de derivados de acido 1,2,3-4-tetrahidro-isoquinolin-2-carboxilico.
UY26577A1 (es)	2001-04-30	" derivados de ácido 1,2,3,4,-tetrahidroquinolin-2-carboxílico sustituidos, procedimientos para su preparación, su uso para la preparación de medicamentos y medicamentos que contienen estos compuestos."